TrialBlood advances2021

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

François Lemonnier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.